A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis - Trial NCT06339242
Access comprehensive clinical trial information for NCT06339242 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jiangsu Province Nanjing Brain Hospital and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jiangsu Province Nanjing Brain Hospital
Timeline & Enrollment
Phase 2
Jan 01, 2024
Jan 31, 2026
Primary Outcome
LM-PFS๏ผprogression-free survival๏ผ,LM-ORR๏ผObjective response rate๏ผ
Summary
Leptomeningeal metastasis is a fatal complication of advanced lung cancer. There is no
 standard treatment for leptomeningeal metastasis after third-generation EGFR-TKIs. The
 Furmonertinib prototype persists longer in brain tissue, and its metabolites can also
 penetrate the blood-brain barrier. Ommaya cystlateral ventricle chemotherapy can quickly
 control the progression of intracranial lesions. The aim of this study is to evaluate the LM
 progression-free survival (LM-PFS) of Furmonertinib combined with lateral ventricular
 chemotherapy in the treatment of leptomeningeal metastatic NSCLC after third-generation
 EGFR-TKIs resistance.
Data Source
ClinicalTrials.gov
NCT06339242
Non-Device Trial